Ildong Pharmaceutical Co., Ltd.

KOSE:A249420 Stock Report

Market Cap: ₩466.5b

Ildong Pharmaceutical Future Growth

Future criteria checks 4/6

Ildong Pharmaceutical is forecast to grow earnings and revenue by 75.1% and 6.9% per annum respectively. EPS is expected to grow by 75.6% per annum. Return on equity is forecast to be 22.6% in 3 years.

Key information

75.1%

Earnings growth rate

75.6%

EPS growth rate

Pharmaceuticals earnings growth35.4%
Revenue growth rate6.9%
Future return on equity22.6%
Analyst coverage

Low

Last updated10 May 2024

Recent future growth updates

Recent updates

Revenues Not Telling The Story For Ildong Pharmaceutical Co., Ltd. (KRX:249420) After Shares Rise 33%

Aug 20
Revenues Not Telling The Story For Ildong Pharmaceutical Co., Ltd. (KRX:249420) After Shares Rise 33%

Is Ildong Pharmaceutical (KRX:249420) A Risky Investment?

Aug 12
Is Ildong Pharmaceutical (KRX:249420) A Risky Investment?

If You Had Bought Ildong Pharmaceutical (KRX:249420) Shares A Year Ago You'd Have Earned 18% Returns

Jan 01
If You Had Bought Ildong Pharmaceutical (KRX:249420) Shares A Year Ago You'd Have Earned 18% Returns

Earnings and Revenue Growth Forecasts

KOSE:A249420 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026726,00060,00069,00084,0001
12/31/2025685,50053,80065,00080,0001
12/31/2024626,00038,80050,00065,0001
3/31/2024605,800-69,347-44,348-26,896N/A
12/31/2023600,758-78,928-51,785-36,615N/A
9/30/2023601,608-134,294-86,582-68,391N/A
6/30/2023615,710-105,042-78,573-62,172N/A
3/31/2023624,122-30,654-71,129-55,437N/A
12/31/2022637,714-141,585-71,814-53,541N/A
9/30/2022628,484-181,371-63,675-48,202N/A
6/30/2022607,365-169,297-40,716-22,525N/A
3/31/2022586,512-208,169-26,449-6,328N/A
12/31/2021560,132-99,705-30,867-11,366N/A
9/30/2021556,191-24,892-15,4504,822N/A
6/30/2021560,494-19,289-8,9567,132N/A
3/31/2021556,360-24,652-17,467-2,102N/A
12/31/2020561,845-13,0192,44219,366N/A
9/30/2020544,875-14,649-1,18516,476N/A
6/30/2020527,837-20,373-4,54915,155N/A
3/31/2020526,985-20,4559,77328,138N/A
12/31/2019517,468-13,44424,04341,366N/A
9/30/2019526,6014,34446,44063,654N/A
6/30/2019525,06312,29653,31970,151N/A
3/31/2019514,10512,30854,21872,736N/A
12/31/2018503,90712,72146,25766,647N/A
9/30/2018486,54019,74716,41256,675N/A
6/30/2018486,26224,53417,34160,184N/A
3/31/2018473,01423,66619,86265,564N/A
12/31/2017460,65119,841N/A73,724N/A
12/31/2016483,22530,189N/A45,977N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A249420 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: A249420 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A249420 is expected to become profitable in the next 3 years.

Revenue vs Market: A249420's revenue (6.9% per year) is forecast to grow slower than the KR market (10.5% per year).

High Growth Revenue: A249420's revenue (6.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A249420's Return on Equity is forecast to be high in 3 years time (22.6%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y